Meet One-on-One with...Astellas Venture Management -Confirmation

Add this event to your calendar:
19/08/2015 11:00 24/08/2015 19:00 America/Los_Angeles Meet One-on-One with...Astellas Venture Management -Confirmation Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA 94080 JLABS Bay Area false DD/MM/YYYY
August
19
Event

Meet One-on-One with...Astellas Venture Management -Confirmation

Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA 94080

August 19, 2015 from 11:00 AM to 19:00 PM (PST)

$10 - $35


JLABS BAY AREA EVENT Congratulations! You have been approved to attend a one-on-one meeting with Astellas Venture Managment. To secure your time slot please register your team who will be in attendance. After receiving confirmation of your registration you will be notified of your meeting time slot. 

Note: Two registrations are required in order to attend the presentation & lunch, and the one-on-one meeting. After registering here for your one-on-one meeting, and if you have not done so yet, please register at https://jlabsbay-astellas2015.eventbrite.com.
 

AVM is the venture group within one of Japan's second largest pharmaceutical company, Astellas Pharma Inc. You may be familiar with some of AVM's successful, local portfolio companies including eFFECTOR Therapeutics and Fate Therapeutics. With hundreds of millions in an evergreen fund, AVM is looking to invest in more private companies in the early stage drug discovery and platform technology across several therapeutic areas, including:

  •  Immunology and Inflammation, Urology, Oncology, Nephrology and Neuroscience
  • Ophthalmology, Hearing Loss, Muscle disorder and Regenerative Medicine.


Also, AVM has another mission by AIM to execute early stage innovative collaborations with Academia and biotech companies. Recent collaboration deals include MD Anderson Cancer Center (oncology drug discovery), Potenza (Immune oncology drug discovery) and Kanyos Therapeutics (Autoimmune drug discovery). AVM/AIM will provide equity and non-dilutive capitals to our portfolios and partners while actively looking for innovative new opportunities. 

Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A 
12:00pm | Networking Lunch 
12:30-5:00pm | One-on-one Meetings* 
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on August 9th.

 AVM Participating Representatives:
Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management read bio»
Takashi Futami | Associate Investment Director, Astellas Venture Management read bio»
Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management read bio»
Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Management read bio»
Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Management read bio» 

About Astellas Venture Management LLC:
Astellas Venture Management LLCAstellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to helping Astellas Pharma Inc. to achieve its strategic goals. The venture capital activity of AVM can be traced back to the year 1999. Through its strategic investments in private early-stage companies, the funds aim to forge relationships with Astellas Pharma, which may lead to larger collaborations in the future. AVM is able to provide portfolio companies with invaluable advice and assistance. Astellas Pharma Inc., the ultimate parent company of AVM, headquartered in Tokyo, was created on April 1, 2005 through the merger of two Japanese pharmaceutical companies. Astellas is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to "Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products." With this philosophy, Astellas focuses on highly specialized therapeutic areas (categories) where there is a high degree of unmet medical needs. 

About Innovation Management:
Innovation ManagementInnovation Management ("AIM") is a newly established organization at Astellas Headquarter. AIM is a dedicated function for external collaboration to promote intake early stage innovation into Astellas R&D. AIM has closed several deals since its inception (Oct, 2013) including Mitokyne (mitochondrial disease drug discovery), Cancer Research UK (oncology target discovery), Harvard Medical School (ophthalmology target discovery), Dana-Farber Cancer Institute (oncology drug discovery) and Proteostasis (genetic disease drug discovery). 

About Astellas Pharma Inc.:
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney Diseases. 

Fees: 
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until September 8th (or sold out). 

One-on-One Meeting
FREE | Application
FREE | Accepted Companies 
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on August 9th. Your application will be reviewed and you will be notified of acceptance by August 21, 2015. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. 

Venue:
Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California 

AVM participating Representatives' biographies:
Sakae Asanuma Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management 
Mr. Sakae Asanuma joined AVM in June 2011. Prior to joining AVM, he served as Director at Yasuda Enterprise Development America, Japan's major VC firm with $800M under management, from 2000 to 2011 and originated Yasuda's biotech investment activities in the US. Based in Bay Area since 2000, he has invested in 30+ US biotech venture companies and deeply involved in the business development discussions with Japanese pharmaceutical companies on behalf of his portfolios. To date, his portfolio companies successfully achieved 9 IPOs and 8 M&As. Prior to Yasuda, he was venture capitalist and buy-side equity analyst from 1988 to 1999, managing $20B+ equity portfolios for Meiji-Yasuda Life Insurance Company (one of the largest life insurance companies in Japan). He holds Master of Business Administration from Carnegie Mellon University. 
Connect with Sakae: Connect on LinkedIn 

 

 


Takashi Futami
 Takashi Futami | Associate Investment Director, Astellas Venture Management 
Mr. Futami joined Astellas Venture Management in Oct 2013. Prior to joining AVM, he worked as a Senior Researcher at Astellas Pharma Inc. He served as a team leader at Oncology Labs of Astellas Pharma, and led a drug discovery research and preclinical development of kinase inhibitor programs in oncology therapeutics area. He also has experiences of collaboration with several institution like The University of Tokyo Hospital, Metabolex Inc. etc. 
Connect with Takashi: Connect on LinkedIn 

 

 


Taro Masunaga
 Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management 
Dr. Masunaga joined Astellas Venture Management in Oct 2013. He has more than 25 years experience of drug discovery research from target discovery to development mainly in Immunology area including transplantation and autoimmune. From 2007 to 2012, he served as associate director to start up the Astellas Research Institute of America (ARIA) which is engaging early drug discovery (target identification, Hit/Lead generation and therapeutic strategy) in transplantation. Prior to joining AVM, he worked as a head of Advanced Drug Discovery (ADD) group in Pharmacology Research Laboratories taking a responsibility for early drug discovery of small molecules for every single focused therapeutic area, Urology, Oncology, Immunology, CNS, Kidney diseases and Frontier diseases. 

 

 


Hideaki Matsuoka
 Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Management 
Dr. Matsuoka joined AVM in October 2014. He has more than 14 years experiences of drug discovery research in the field of immunology, cell biology, and molecular biology at Astellas Pharma Inc., and served as a principal scientist at Astellas Research Institute of America (ARIA) from 2007 to 2010 specifically focusing on early drug discovery (target identification, Hit/Lead generation and therapeutic strategy development) in transplantation. Prior to joining AVM, he served as a senior manager in charge of scientific evaluation at Astellas Innovation Management (AIM) and has a significant track record of leading several partnering deals. 

 

 


Nobuaki Shindoh
 Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Management 
Dr. Shindoh joined AVM in November 2014. He has 18 years experiences of drug discovery research in the field of Oncology, Urology and renal disease at Astellas Pharma Inc. and covers broad range of drug discovery from target identification to clinical development with successful experience in oncology. From 2011-2012, he worked at the Dana-Farber Cancer Institute as a visiting scientist to identify novel drug targets. Since Oct 2013, he served as associate director of Astellas Innovation Management (AIM) in charge of scientific evaluation in the oncology disease area and led the partnering with CRUK. 

 

 



About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.



JLABS Bay Area

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content